Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines aimed at treating various gastrointestinal and cardiorenal conditions both in the United States and internationally. The company's lead product candidate, tenapanor, has successfully completed Phase III clinical trials for treating patients suffering from irritable bowel syndrome with constipation and is also undergoing Phase III trials to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD) undergoing dialysis, a condition known as hyperphosphatemia. Ardelyx is additionally developing RDX013, a potassium secretagogue designed to address elevated serum potassium levels, or hyperkalemia, which is particularly relevant for certain patients with kidney or heart disorders. Furthermore, RDX020 is being investigated as an early-stage program targeting metabolic acidosis, a serious electrolyte imbalance affecting patients with CKD. The company has established collaborations with Kyowa Kirin for development in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. for China, and Knight Therapeutics, Inc. in Canada for commercializing tenapanor in those regions. The company's financial metrics show that the EBITDA is -$29,173,000.00 a key indicator of the company's operational profitability, while the gross profit stands at $367,783,000.00 highlighting its earnings from core operations. The weighted average number of diluted shares outstanding is 241,033,750.00 which reflects potential dilution effects, and the company reported depreciation and amortization expenses of $3,059,000.00 illustrating the wear and tear of its assets. Ardelyx’s stock is identified with the symbol 'ARDX' in the market. Investors may find the stock appealing, as it is affordable at $6.21 making it suitable for budget-conscious individuals. The stock boasts a high average trading volume of 4,703,856.00 indicating strong liquidity and interest from the market. With a market capitalization of $1,432,242,480.00 Ardelyx is classified as a small-cap player, which often indicates growth potential. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth in the Healthcare sector. This positioning enhances its ability to attract attention from both investors and collaborators in the field of biopharmaceuticals.